Search

Your search keyword '"Freytes C"' showing total 216 results
Start Over Author "Freytes C"

Refine your results

more »

more »

more »

more »
216 results on '"Freytes C"'

1. Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes.

Author

Ulrickson, M, Verdonck, L, Wirk, B, Wood, W, Yared, J, Saber, W, Tay, J, Beattie, S, Bredeson, C, Brazauskas, R, He, N, Ahmed, I, Aljurf, M, Askar, M, Atsuta, Y, Badawy, S, Barata, A, Beitinjaneh, A, Bhatt, N, Buchbinder, D, Cerny, J, Ciurea, S, DSouza, A, Dalal, J, Farhadfar, N, Freytes, C, Ganguly, S, Gergis, U, Gerull, S, Lazarus, H, Hahn, T, Hong, S, Inamoto, Y, Khera, N, Kindwall-Keller, T, Kamble, R, Knight, J, Koleva, Y, Kumar, A, Kwok, J, Murthy, H, Olsson, R, Angel Diaz-Perez, M, Rizzieri, D, Seo, S, Chhabra, S, Schoemans, H, Schouten, H, Steinberg, A, Sullivan, K, Szer, J, and Szwajcer, D

Subjects
Hematopoietic cell transplantation, graft-versus-host disease, marital status, overall survival, registries, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Marital Status, Quality of Life
Abstract

BACKGROUND: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. METHODS: We identified patients 40 years of age and older within the Center for International Blood and Marrow Transplant Research registry who underwent hct between January 2008 and December 2015. Marital status before hct was declared as one of: married or living with a partner, single (never married), separated or divorced, and widowed. We performed a multivariable analysis to determine the association of marital status with outcomes after hct. RESULTS: We identified 10,226 allogeneic and 5714 autologous hct cases with, respectively, a median follow-up of 37 months (range: 1-102 months) and 40 months (range: 1-106 months). No association between marital status and overall survival was observed in either the allogeneic (p = 0.58) or autologous (p = 0.17) setting. However, marital status was associated with grades 2-4 acute graft-versus-host disease (gvhd), p < 0.001, and chronic gvhd, p = 0.04. The risk of grades 2-4 acute gvhd was increased in separated compared with married patients [hazard ratio (hr): 1.13; 95% confidence interval (ci): 1.03 to 1.24], and single patients had a reduced risk of grades 2-4 acute gvhd (hr: 0.87; 95% ci: 0.77 to 0.98). The risk of chronic gvhd was lower in widowed compared with married patients (hr: 0.82; 95% ci: 0.67 to 0.99). CONCLUSIONS: Overall survival after hct is not influenced by marital status, but associations were evident between marital status and grades 2-4 acute and chronic gvhd. To better appreciate the effects of marital status and social support, future research should consider using validated scales to measure social support and patient and caregiver reports of caregiver commitment, and to assess health-related quality of life together with health care utilization.

Published
2020

2. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis

Author

Mahindra, A, Hari, P, Fraser, R, Fei, M, Huang, J, Berdeja, J, Callander, N, Costa, L, Diaz, M A, Freytes, C, Gale, R P, Girnius, S, Holmberg, L, Kharfan-Dabaja, M, Kumar, S, Kyle, R, Lazarus, H, Lee, C, Maiolino, A, Moreb, J, Nishihori, T, Pawarode, A, Saad, A, Savani, B N, Schriber, J, William, B, Wirk, B M, Krishnan, A, Nieto, Y, and D’Souza, A

Published
2017
Full Text
View/download PDF

3. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Author

Klyuchnikov, E, Bacher, U, Woo Ahn, K, Carreras, J, Kröger, N M, Hari, P N, Ku, G H, Ayala, E, Chen, A I, Chen, Y-B, Cohen, J B, Freytes, C O, Gale, R P, Kamble, R T, Kharfan-Dabaja, M A, Lazarus, H M, Martino, R, Mussetti, A, Savani, B N, Schouten, H C, Usmani, S Z, Wiernik, P H, Wirk, B, Smith, S M, Sureda, A, and Hamadani, M

Published
2016
Full Text
View/download PDF

4. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

Author

Uy, G L, Costa, L J, Hari, P N, Zhang, M-J, Huang, J-X, Anderson, K C, Bredeson, C N, Callander, N S, Cornell, R F, Perez, M A D, Dispenzieri, A, Freytes, C O, Gale, R P, Garfall, A, Gertz, M A, Gibson, J, Hamadani, M, Lazarus, H M, Kalaycio, M E, Kamble, R T, Kharfan-Dabaja, M A, Krishnan, A Y, Kumar, S K, Kyle, R A, Landau, H J, Lee, C H, Maiolino, A, Marks, D I, Mark, T M, Munker, R, Nishihori, T, Olsson, R F, Ramanathan, M, Rodriguez, T E, Saad, A A, Savani, B N, Schiller, G J, Schouten, H C, Schriber, J R, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, E A, Tay, J, To, L B, Vesole, D H, Vogl, D T, Wagner, J L, Wirk, B, Wood, W A, and D'Souza, A

Published
2015
Full Text
View/download PDF

5. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma

Author

Satwani, P, Ahn, K W, Carreras, J, Abdel-Azim, H, Cairo, M S, Cashen, A, Chen, A I, Cohen, J B, Costa, L J, Dandoy, C, Fenske, T S, Freytes, C O, Ganguly, S, Gale, R P, Ghosh, N, Hertzberg, M S, Hayashi, R J, Kamble, R T, Kanate, A S, Keating, A, Kharfan-Dabaja, M A, Lazarus, H M, Marks, D I, Nishihori, T, Olsson, R F, Prestidge, T D, Rolon, J M, Savani, B N, Vose, J M, Wood, W A, Inwards, D J, Bachanova, V, Smith, S M, Maloney, D G, Sureda, A, and Hamadani, M

Published
2015
Full Text
View/download PDF

7. Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites

Author

Solano-Páez P, Fonseca A, Baroni LV, Amayiri N, Pérez-Somarriba Moreno Marta, Freytes C, Quiroga E, Rivero M, Márquez J, Lassaletta Á, and Bouffet E

Subjects
Pediatric low grade glioma, Ascites, MAPK pathway, Ventriculo peritoneal shunt, RAS
Abstract

Introduction Ventriculo-peritoneal shunt (VPS) related ascites is a rare complication of pediatric low grade gliomas (pLGG). Physiopathology of this complication is not fully understood and there is paucity of data regarding the molecular profile of pLGG gliomas complicating with ascites and the optimal management of this unusual event. Methods International multi-institutional retrospective analysis of patients diagnosed with BRAF altered pLGG and ascites arising as a complication of VPS. Demographics, tumor characteristics, therapeutic approaches and outcomes were recorded. Results Nineteen patients were identified. Median age at diagnosis was 14 months (R: 2-144). Most patients (17; 89.4%) presented with lesions involving the optic pathway. Mean tumor standard volume was 34.8 cm(2) (R: 12.5-85.4). Pilocytic Astrocytoma was the most frequent histological diagnosis (14;7 3.7%). Eight (42.1%) tumors harbored BRAF V600-E mutation and seven (36.8%) KIAA1549 fusion. The onset of ascites was documented at a median time of 5 months following VPS insertion. Four (21%) patients were managed with paracentesis only, 7(36.8%) required both paracentesis and shunt diversion, 7(36.8%) required only a shunt diversion and 1 (5.2%) patient was managed conservatively. Chemotherapy regimen was changed in 10 patients following ascites. Eight patients received targeted therapy (4 dabrafenib/4 trametinib) and 5 were radiated. There were eleven survivors with a median OS of 69 months (R: 3-144). Conclusions Ascites is an early feature in the clinical course of young patients with midline BRAF altered pLGG, with high mortality rate observed in our cohort. The hypothesis of ascites as an adverse prognostic factor in pLGG warrants further prospective research.

Published
2022

15. Treatment response of CNS high-grade neuroepithelial tumors with MN1 alteration

Author

Baroni LV, Rugilo C, Lubieniecki F, Sampor C, Freytes C, Nobre L, Hansford JR, Malalasekera VS, Zapotocky M, Dodgshun A, Martinez OC, Morales-La Madrid A, Lavarino C, Suñol M, Rutkowski S, Schuller U, Bouffet E, Ramaswamy V, and Alderete D

Subjects
neuroepithelial tumor, astroblastoma, CNS HGNET-MN1, MN1, ependymoma
Abstract

Central nervous system high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1) is a rare recently described entity. Fourteen CNS HGNET-MN1 patients were identified using genome-wide methylation arrays/RT-PCR across seven institutions. All patients had surgery (gross total resection: 10; subtotal resection: four) as initial management followed by observation alone in three patients, followed by radiotherapy in eight patients (focal: five; craniospinal: two; CyberKnife: one) and systemic chemotherapy in three patients. Seven patients relapsed; five local and two metastatic, despite adjuvant radiotherapy, of which three died. Treatment of CNS HGNET-MN1 remains a major treatment challenge despite aggressive surgical resections and upfront radiotherapy, warranting new approaches to this rare malignancy.

Published
2020

17. Pre-transplant marital status and hematopoietic cell transplantation outcomes

Author

Tay, J., Beattie, S., Bredeson, C., Brazauskas, R., He, N., Ahmed, I. A., Aljurf, M., Askar, M., Atsuta, Y., Badawy, S., Barata, A., Beitinjaneh, A. M., Bhatt, N. S., Buchbinder, D., Cerny, J., Ciurea, S., D'Souza, A., Dalal, J., Farhadfar, N., Freytes, C. O., Ganguly, S., Gergis, U., Gerull, S., Lazarus, H. M., Hahn, T., Hong, S., Inamoto, Y., Khera, N., Kindwall-Keller, T., Kamble, R. T., Knight, J. M., Koleva, Y. N., Kumar, A., Kwok, J., Murthy, H. S., Olsson, R. F., Angel Diaz-Perez, M., Rizzieri, D., Seo, S., Chhabra, S., Schoemans, H., Schouten, H. C., Steinberg, A., Sullivan, K. M., Szer, J., Szwajcer, D., Ulrickson, M. L., Verdonck, L. F., Wirk, B., Wood, W. A., Yared, J. A., Saber, W., Tay, J., Beattie, S., Bredeson, C., Brazauskas, R., He, N., Ahmed, I. A., Aljurf, M., Askar, M., Atsuta, Y., Badawy, S., Barata, A., Beitinjaneh, A. M., Bhatt, N. S., Buchbinder, D., Cerny, J., Ciurea, S., D'Souza, A., Dalal, J., Farhadfar, N., Freytes, C. O., Ganguly, S., Gergis, U., Gerull, S., Lazarus, H. M., Hahn, T., Hong, S., Inamoto, Y., Khera, N., Kindwall-Keller, T., Kamble, R. T., Knight, J. M., Koleva, Y. N., Kumar, A., Kwok, J., Murthy, H. S., Olsson, R. F., Angel Diaz-Perez, M., Rizzieri, D., Seo, S., Chhabra, S., Schoemans, H., Schouten, H. C., Steinberg, A., Sullivan, K. M., Szer, J., Szwajcer, D., Ulrickson, M. L., Verdonck, L. F., Wirk, B., Wood, W. A., Yared, J. A., and Saber, W.

Abstract

Background Evidence about the impact of marital status before hematopoietic cell transplantation (HCT) on outcomes after HCT is conflicting. Methods We identified patients 40 years of age and older within the Center for International Blood and Marrow Transplant Research registry who underwent HCT between January 2008 and December 2015. Marital status before HCT was declared as one of: married or living with a partner, single (never married), separated or divorced, and widowed. We performed a multivariable analysis to determine the association of marital status with outcomes after HCT. Results We identified 10,226 allogeneic and 5714 autologous HCT cases with, respectively, a median follow-up of 37 months (range: 1-102 months) and 40 months (range: 1-106 months). No association between marital status and overall survival was observed in either the allogeneic (p = 0.58) or autologous (p = 0.17) setting. However, marital status was associated with grades 2-4 acute graft-versus-host disease (GVHD), p < 0.001, and chronic GVHD, p = 0.04. The risk of grades 2-4 acute GVHD was increased in separated compared with married patients [hazard ratio (FIR): 1.13; 95% confidence interval (CI): 1.03 to 1.24], and single patients had a reduced risk of grades 2-4 acute GVHD (FIR: 0.87; 95% CI: 0.77 to 0.98). The risk of chronic GVHD was lower in widowed compared with married patients (FIR: 0.82; 95% CI: 0.67 to 0.99). Conclusions Overall survival after HCT is not influenced by marital status, but associations were evident between marital status and grades 2-4 acute and chronic GVHD. To better appreciate the effects of marital status and social support, future research should consider using validated scales to measure social support and patient and caregiver reports of caregiver commitment, and to assess health-related quality of life together with health care utilization.

Published
2020
Full Text
View/download PDF

18. TREATMENT RESPONSE OF CNS HIGH-GRADE NEUROEPITHELIAL TUMORS WITH MN1 ALTERATION

Author

Baroni, LV, Rugilo, C, Lubieniecki, F, Sampor, C, Freytes, C, Nobre, L, Hansford, JR, Malalasekera, VS, Zapotocky, M, Dodgshun, A, Ramaswamy, V, Alderete, D, Baroni, LV, Rugilo, C, Lubieniecki, F, Sampor, C, Freytes, C, Nobre, L, Hansford, JR, Malalasekera, VS, Zapotocky, M, Dodgshun, A, Ramaswamy, V, and Alderete, D

Abstract

Central nervous system high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1) is a rare recently described entity. Fourteen CNS HGNET-MN1 patients were identified using genome-wide methylation arrays/RT-PCR across seven institutions. All patients had surgery (gross total resection: 10; subtotal resection: four) as initial management followed by observation alone in three patients, followed by radiotherapy in eight patients (focal: five; craniospinal: two; CyberKnife: one) and systemic chemotherapy in three patients. Seven patients relapsed; five local and two metastatic, despite adjuvant radiotherapy, of which three died. Treatment of CNS HGNET-MN1 remains a major treatment challenge despite aggressive surgical resections and upfront radiotherapy, warranting new approaches to this rare malignancy.

Published
2020

20. Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

Author

Tay, J., primary, Beattie, S., additional, Bredeson, C., additional, Brazauskas, R., additional, He, N., additional, Ahmed, I. A., additional, Aljurf, M., additional, Askar, M., additional, Atsuta, Y., additional, Badawy, S., additional, Barata, A., additional, Beitinjaneh, A. M., additional, Bhatt, N. S., additional, Buchbinder, D., additional, Cerny, J., additional, Ciurea, S., additional, D’Souza, A., additional, Dalal, J., additional, Farhadfar, N., additional, Freytes, C. O., additional, Ganguly, S., additional, Gergis, U., additional, Gerull, S., additional, Lazarus, H. M., additional, Hahn, T., additional, Hong, S., additional, Inamoto, Y., additional, Khera, N., additional, Kindwall-Keller, T., additional, Kamble, R. T., additional, Knight, J. M., additional, Koleva, Y. N., additional, Kumar, A., additional, Kwok, J., additional, Murthy, H. S., additional, Olsson, R. F., additional, Angel Diaz-Perez, M., additional, Rizzieri, D., additional, Seo, S., additional, Chhabra, S., additional, Schoemans, H., additional, Schouten, H. C., additional, Steinberg, A., additional, Sullivan, K. M., additional, Szer, J., additional, Szwajcer, D., additional, Ulrickson, M. L., additional, Verdonck, L. F., additional, Wirk, B., additional, Wood, W. A., additional, Yared, J. A., additional, and Saber, W., additional

Published
2020
Full Text
View/download PDF

26. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J, primary, Mullane, Kathleen M, additional, Cornely, Oliver A, additional, Boeckh, Michael J, additional, Brown, Janice Wes, additional, Pergam, Steven A, additional, Trociukas, Igoris, additional, Žák, Pavel, additional, Craig, Michael D, additional, Papanicolaou, Genovefa A, additional, Velez, Juan D, additional, Panse, Jens, additional, Hurtado, Kimberly, additional, Fernsler, Doreen A, additional, Stek, Jon E, additional, Pang, Lei, additional, Su, Shu-Chih, additional, Zhao, Yanli, additional, Chan, Ivan S F, additional, Kaplan, Susan S, additional, Parrino, Janie, additional, Lee, Ingi, additional, Popmihajlov, Zoran, additional, Annunziato, Paula W, additional, Arvin, Ann, additional, Basso, AC, additional, Bonvehi, P, additional, Cerana, S, additional, Dictar, MO, additional, Campbell, P, additional, Playford, G, additional, Sasadeusz, J, additional, Maertens, J, additional, Poire, X, additional, Sellesag, D, additional, Schots, R, additional, Theunissen, K, additional, Willems, E, additional, Alves, RS, additional, Camargo, JFC, additional, Castro, NS, additional, Maria Fogliatto, L, additional, Rodrigo, O, additional, Courture, F, additional, McGeer, A, additional, Miller, M, additional, Combariza, JF, additional, Sossa, CL, additional, Velez, JD, additional, Nemet, D, additional, Ostojic Kolonic, S, additional, Jebavy, L, additional, Mayer, J, additional, Novak, J, additional, Pohlreich, D, additional, Maldonado, B, additional, Gastinne, T, additional, Karlin, L, additional, Launay, O, additional, Cornely, OA, additional, Duerk, HA, additional, Haenel, M, additional, Heinz, W, additional, Kaufmann, M, additional, Panse, J, additional, Teschner, D, additional, Verbeek, M, additional, Wulf, G, additional, Aviv, F, additional, Grisariu, S, additional, Nagler, A, additional, Yeshurun, M, additional, Bosi, A, additional, Corradini, P, additional, Martinelli, G, additional, Onida, F, additional, Rambaldi, A, additional, Velardi, A, additional, Trociukas, I, additional, Gomez, AD, additional, Wondergem, MJ, additional, Ypma, PF, additional, Fanilla, E, additional, Moreno Larrea, MDC, additional, Abecasis, MM, additional, Ferreira, RB, additional, Geraldes, C, additional, Castro, J, additional, Afanasyev, BV, additional, Kruchkova, IV, additional, Zaritskiy, AY, additional, Cheong, JW, additional, Kim, SJ, additional, Lee, DG, additional, Yoon, SS, additional, Aguado Bueno, B, additional, Jarque Ramos, I, additional, Solano Vercet, C, additional, Cherif, H, additional, Ljungman, P, additional, Vaht, K, additional, Cook, G, additional, Kanfer, E, additional, Milligan, DW, additional, Parker, A, additional, Akard, L, additional, Bachier, C, additional, Ball, ED, additional, Betts, FR, additional, Braunschweig, I, additional, Brown, JM, additional, Carroll, MP, additional, Chandrasekar, PH, additional, Collins, R, additional, Cooper, B, additional, Craig, M, additional, D'Cunha, N, additional, Donato, ML, additional, Essell, J, additional, Flomenberg, P, additional, Freifeld, A, additional, Freytes, C, additional, Guarino, MJ, additional, Hall, MC, additional, Heimenz, JW, additional, High, KP, additional, Isola, LM, additional, Kaminer, L, additional, Klein, LM, additional, Janakiraman, N, additional, Kane, K, additional, Komanduri, K, additional, Krijanovski, OI, additional, Lawrence, SJ, additional, Leis, JF, additional, Lill, M, additional, Longo, WL, additional, Lynch, JP, additional, Mattar, BI, additional, Mehta, J, additional, Mullane, KM, additional, Nathan, S, additional, Papanicolaou, GA, additional, Pergam, SA, additional, Roy, V, additional, Rybka, W, additional, Safah, H, additional, Saltzman, D, additional, Segal, GM, additional, Selby, GB, additional, Schuster, MW, additional, Shoham, S, additional, Sloan, JM, additional, Strasfeld, LM, additional, Styler, M, additional, Sullivan, K, additional, Tse, W, additional, Vance, EA, additional, Winston, DJ, additional, and Yanovich, S, additional

Published
2018
Full Text
View/download PDF

27. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Author

Kumar, S K, primary, Dispenzieri, A, additional, Fraser, R, additional, Mingwei, F, additional, Akpek, G, additional, Cornell, R, additional, Kharfan-Dabaja, M, additional, Freytes, C, additional, Hashmi, S, additional, Hildebrandt, G, additional, Holmberg, L, additional, Kyle, R, additional, Lazarus, H, additional, Lee, C, additional, Mikhael, J, additional, Nishihori, T, additional, Tay, J, additional, Usmani, S, additional, Vesole, D, additional, Vij, R, additional, Wirk, B, additional, Krishnan, A, additional, Gasparetto, C, additional, Mark, T, additional, Nieto, Y, additional, Hari, P, additional, and D'Souza, A, additional

Published
2017
Full Text
View/download PDF

28. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

Author

Uy, G. L., Costa, L. J., Hari, P. N., Zhang, M-J, Huang, J-X, Anderson, K. C., Bredeson, C. N., Callander, N. S., Cornell, R. F., Perez, M. A. D., Dispenzieri, A., Freytes, C. O., Gale, R. P., Garfall, A., Gertz, M. A., Gibson, J., Hamadani, M., Lazarus, H. M., Kalaycio, M. E., Kamble, R. T., Kharfan-Dabaja, M. A., Krishnan, A. Y., Kumar, S. K., Kyle, R. A., Landau, H. J., Lee, C. H., Maiolino, A., Marks, D. I., Mark, T. M., Munker, R., Nishihori, T., Olsson, R. F., Ramanathan, M., Rodriguez, T. E., Saad, A. A., Savani, B. N., Schiller, G. J., Schouten, H. C., Schriber, J. R., Scott, E., Seo, S., Sharma, M., Ganguly, S., Stadtmauer, E. A., Tay, J., To, L. B., Vesole, D. H., Vogl, D. T., Wagner, J. L., Wirk, B., Wood, W. A., D'Souza, A., Uy, G. L., Costa, L. J., Hari, P. N., Zhang, M-J, Huang, J-X, Anderson, K. C., Bredeson, C. N., Callander, N. S., Cornell, R. F., Perez, M. A. D., Dispenzieri, A., Freytes, C. O., Gale, R. P., Garfall, A., Gertz, M. A., Gibson, J., Hamadani, M., Lazarus, H. M., Kalaycio, M. E., Kamble, R. T., Kharfan-Dabaja, M. A., Krishnan, A. Y., Kumar, S. K., Kyle, R. A., Landau, H. J., Lee, C. H., Maiolino, A., Marks, D. I., Mark, T. M., Munker, R., Nishihori, T., Olsson, R. F., Ramanathan, M., Rodriguez, T. E., Saad, A. A., Savani, B. N., Schiller, G. J., Schouten, H. C., Schriber, J. R., Scott, E., Seo, S., Sharma, M., Ganguly, S., Stadtmauer, E. A., Tay, J., To, L. B., Vesole, D. H., Vogl, D. T., Wagner, J. L., Wirk, B., Wood, W. A., and D'Souza, A.

Abstract

In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-Ha in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (>= 0.5 x 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (>= 20 x 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-Ha have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

Published
2015
Full Text
View/download PDF

29. Allogeneic hematopoietic cell transplant for AML : no impact of pre-transplant extramedullary disease on outcome

Author

Goyal, S. D., Zhang, M-J, Wang, H-L, Akpek, G., Copelan, E. A., Freytes, C., Gale, R. P., Hamadani, M., Inamoto, Y., Kamble, R. T., Lazarus, H. M., Marks, D. I., Nishihori, T., Olsson, R. F., Reshef, R., Ritchie, D. S., Saber, W., Savani, B. N., Seber, A., Shea, T. C., Tallman, M. S., Wirk, B., Bunjes, D. W., Devine, S. M., de Lima, M., Weisdorf, D. J., Uy, G. L., Goyal, S. D., Zhang, M-J, Wang, H-L, Akpek, G., Copelan, E. A., Freytes, C., Gale, R. P., Hamadani, M., Inamoto, Y., Kamble, R. T., Lazarus, H. M., Marks, D. I., Nishihori, T., Olsson, R. F., Reshef, R., Ritchie, D. S., Saber, W., Savani, B. N., Seber, A., Shea, T. C., Tallman, M. S., Wirk, B., Bunjes, D. W., Devine, S. M., de Lima, M., Weisdorf, D. J., and Uy, G. L.

Abstract

The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% confidence interval (Cl) 0.91-1.09), LFS (0.98, 0.89-1.09), TRM (relative risk 0.92, 95% CI 0.80-1.16, P=0.23) or relapse (relative risk= 1.03, 95% CI, 0.92-1.16; P=0.62). Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature.

Published
2015
Full Text
View/download PDF

30. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma

Author

Satwani, P., Ahn, K. W., Carreras, J., Abdel-Azim, H., Cairo, M. S., Cashen, A., Chen, A. I., Cohen, J. B., Costa, L. J., Dandoy, C., Fenske, T. S., Freytes, C. O., Ganguly, S., Gale, R. P., Ghosh, N., Hertzberg, M. S., Hayashi, R. J., Kamble, R. T., Kanate, A. S., Keating, A., Kharfan-Dabaja, M. A., Lazarus, H. M., Marks, D. I., Nishihori, T., Olsson, R. F., Prestidge, T. D., Rolon, J. M., Savani, B. N., Vose, J. M., Wood, W. A., Inwards, D. J., Bachanova, V., Smith, S. M., Maloney, D. G., Sureda, A., Hamadani, M., Satwani, P., Ahn, K. W., Carreras, J., Abdel-Azim, H., Cairo, M. S., Cashen, A., Chen, A. I., Cohen, J. B., Costa, L. J., Dandoy, C., Fenske, T. S., Freytes, C. O., Ganguly, S., Gale, R. P., Ghosh, N., Hertzberg, M. S., Hayashi, R. J., Kamble, R. T., Kanate, A. S., Keating, A., Kharfan-Dabaja, M. A., Lazarus, H. M., Marks, D. I., Nishihori, T., Olsson, R. F., Prestidge, T. D., Rolon, J. M., Savani, B. N., Vose, J. M., Wood, W. A., Inwards, D. J., Bachanova, V., Smith, S. M., Maloney, D. G., Sureda, A., and Hamadani, M.

Abstract

Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/ refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age < 30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995 and 2010. The probabilities of PFS at 1, 5 and 10 years were 66% (95% confidence interval (CI): 62-70), 52% (95% CI: 48-57) and 47% (95% CI: 42-51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score >= 90, no extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with time from diagnosis to first relapse of < 1 year had a significantly inferior PFS. A prognostic model for PFS was developed that stratified patients into low-, intermediate-and high-risk groups, predicting for 5-year PFS probabilities of 72% (95% CI: 64-80), 53% (95% CI: 47-59) and 23% (95% CI: 9-36), respectively. This large study identifies a group of CAYA patients with relapsed/refractory HL who are at high risk of progression after AutoHCT. Such patients should be targeted for novel therapeutic and/or maintenance approaches post-AutoHCT.

Published
2015
Full Text
View/download PDF

31. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome

Author

Goyal, SD, Zhang, M-J, Wang, H-L, Akpek, G, Copelan, EA, Freytes, C, Gale, RP, Hamadani, M, Inamoto, Y, Kamble, RT, Lazarus, HM, Marks, DI, Nishihori, T, Olsson, RF, Reshef, R, Ritchie, DS, Saber, W, Savani, BN, Seber, A, Shea, TC, Tallman, MS, Wirk, B, Bunjes, DW, Devine, SM, de Lima, M, Weisdorf, DJ, Uy, GL, Goyal, SD, Zhang, M-J, Wang, H-L, Akpek, G, Copelan, EA, Freytes, C, Gale, RP, Hamadani, M, Inamoto, Y, Kamble, RT, Lazarus, HM, Marks, DI, Nishihori, T, Olsson, RF, Reshef, R, Ritchie, DS, Saber, W, Savani, BN, Seber, A, Shea, TC, Tallman, MS, Wirk, B, Bunjes, DW, Devine, SM, de Lima, M, Weisdorf, DJ, and Uy, GL

Abstract

The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% confidence interval (CI) 0.91-1.09), LFS (0.98, 0.89-1.09), TRM (relative risk 0.92, 95% CI 0.80-1.16, P=0.23) or relapse (relative risk=1.03, 95% CI, 0.92-1.16; P=0.62). Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature.

Published
2015

32. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Author

Klyuchnikov, E, primary, Bacher, U, additional, Woo Ahn, K, additional, Carreras, J, additional, Kröger, N M, additional, Hari, P N, additional, Ku, G H, additional, Ayala, E, additional, Chen, A I, additional, Chen, Y-B, additional, Cohen, J B, additional, Freytes, C O, additional, Gale, R P, additional, Kamble, R T, additional, Kharfan-Dabaja, M A, additional, Lazarus, H M, additional, Martino, R, additional, Mussetti, A, additional, Savani, B N, additional, Schouten, H C, additional, Usmani, S Z, additional, Wiernik, P H, additional, Wirk, B, additional, Smith, S M, additional, Sureda, A, additional, and Hamadani, M, additional

Published
2015
Full Text
View/download PDF

33. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Author

Kumar, S K, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, and D'Souza, A

Abstract

Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24−48 months post-AHCT). Over three periods (2001–2004, 2005–2008, 2009–2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35–38%. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.

Published
2018
Full Text
View/download PDF

34. Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation

Author

Freytes, C O, primary, Vesole, D H, additional, LeRademacher, J, additional, Zhong, X, additional, Gale, R P, additional, Kyle, R A, additional, Reece, D E, additional, Gibson, J, additional, Schouten, H C, additional, McCarthy, P L, additional, Lonial, S, additional, Krishnan, A Y, additional, Dispenzieri, A, additional, and Hari, P N, additional

Published
2013
Full Text
View/download PDF

35. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma

Author

Ringdén, O, primary, Shrestha, S, additional, da Silva, G T, additional, Zhang, M-J, additional, Dispenzieri, A, additional, Remberger, M, additional, Kamble, R, additional, Freytes, C O, additional, Gale, R P, additional, Gibson, J, additional, Gupta, V, additional, Holmberg, L, additional, Lazarus, H, additional, McCarthy, P, additional, Meehan, K, additional, Schouten, H, additional, Milone, G A, additional, Lonial, S, additional, and Hari, P N, additional

Published
2011
Full Text
View/download PDF

37. The Graft-Versus-Myeloma Effect Using Non-Myeloablative Or Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Author

Ringden, O., primary, Barrett, J., additional, Shrestha, S., additional, Tunes, da Silva G., additional, Zhang, M.-J., additional, Dispenzieri, A., additional, Remberger, M., additional, Kamble, R., additional, Freytes, C., additional, Gale, R.P., additional, Gibson, J., additional, Gupta, V., additional, Holmberg, L., additional, Lazarus, H., additional, McCarthy, P., additional, Meehan, K., additional, Schouten, H., additional, Milone, G.A., additional, Lonial, S., additional, and Hari, P.N., additional

Published
2010
Full Text
View/download PDF

38. Allogeneic hematopoietic cell transplantation for metastatic breast cancer

Author

Ueno, N T, primary, Rizzo, J D, additional, Demirer, T, additional, Cheng, Y C, additional, Hegenbart, U, additional, Zhang, M-J, additional, Bregni, M, additional, Carella, A, additional, Blaise, D, additional, Bashey, A, additional, Bitran, J D, additional, Bolwell, B J, additional, Elfenbein, G J, additional, Fields, K K, additional, Freytes, C O, additional, Gale, R P, additional, Lazarus, H M, additional, Champlin, R E, additional, Stiff, P J, additional, and Niederwieser, D, additional

Published
2007
Full Text
View/download PDF

45. Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer

Author

Adkins, D., primary, Brown, R., additional, Trinkaus, K., additional, Maziarz, R., additional, Luedke, S., additional, Freytes, C., additional, Needles, B., additional, Wienski, D., additional, Fracasso, P., additional, Pluard, T., additional, Moriconi, W., additional, Ryan, T., additional, Hoelzer, K., additional, Safdar, S., additional, Rearden, T., additional, Rodriguez, G., additional, Khoury, H., additional, Vij, R., additional, and DiPersio, J., additional

Published
1999
Full Text
View/download PDF

46. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

Author

Antman, K H, primary, Rowlings, P A, additional, Vaughan, W P, additional, Pelz, C J, additional, Fay, J W, additional, Fields, K K, additional, Freytes, C O, additional, Gale, R P, additional, Hillner, B E, additional, Holland, H K, additional, Kennedy, M J, additional, Klein, J P, additional, Lazarus, H M, additional, McCarthy, P L, additional, Saez, R, additional, Spitzer, G, additional, Stadtmauer, E A, additional, Williams, S F, additional, Wolff, S, additional, Sobocinski, K A, additional, Armitage, J O, additional, and Horowitz, M M, additional

Published
1997
Full Text
View/download PDF

49. Autologous stem cell transplantation in multiple myeloma patients <60 vs ?60 years of age.

Author

Reece, D. E., Bredeson, C., Pérez, W. S., Jagannath, S., Zhang, M. J., Ballen, K. K., Elfenbein, G. J., Freytes, C. O., Gale, R. P., Gertz, M. A., Gibson, J., Giralt, S. A., Keating, A., Kyle, R. A., Maharaj, D., Marcellus, D., McCarthy, P. L., Milone, G. A., Nimer, S. D., and Pavlovsky, S.

Subjects
STEM cells, BLOOD cells, BONE marrow transplantation, MULTIPLE myeloma, OLDER people, PATIENTS
Abstract

Summary:The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ?the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher ß2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ?60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT >12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.Bone Marrow Transplantation (2003) 32, 1135-1143. doi:10.1038/sj.bmt.1704288 [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

50. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

Author

Lazarus, H. M., Loberiza, F. R., Zhang, M.-J., Armitage, J. O., Ballen, K. K., Bashey, A., Bolwell, B. J., Burns, L. J., Freytes, C. O., Gale, R. P., Gibson, J., Herzig, R. H., LeMaistre, C. F., Marks, D., Mason, J., Miller, A. M., Milone, G. A., Pavlovsky, S., Reece, D. E., and Rizzo, J. D.

Subjects
AUTOTRANSPLANTATION, HODGKIN'S disease, AUTOGRAFTS, BONE marrow transplantation
Abstract

Although patients with relapsed Hodgkin’s disease have a poor prognosis with conventional therapies, high-dose chemotherapy and autologous hematopoietic stem cell transplantation (autotransplantation) may provide long-term progression-free survival. We reviewed data from the Autologous Blood and Marrow Transplant Registry (ABMTR) to determine relapse, disease-free survival, overall survival, and prognostic factors in this group of patients. Detailed records from the ABMTR on 414 patients with Hodgkin’s disease in first relapse (n = 295) or second complete remission (CR) (n = 119) receiving an autotransplant from 1989 to 1995 were reviewed. Median age was 29 (range, 7–64) years. Median time from diagnosis to relapse was 18 (range, 6–219) months; median time from relapse to transplant was 5 (range, <1–215) months. Most patients received high-dose chemotherapy without total body irradiation for conditioning (n = 370). The most frequently used high-dose regimen was cyclophosphamide, BCNU, VP-16 (CBV) (n = 240). The graft consisted of bone marrow (n = 246), blood stem cells (n = 112), or both (n = 56). Median follow-up was 46 (range, 5–96) months. One hundred-day mortality (95% confidence interval) was 7 (5–9)%. One hundred and sixty-five of 295 patients (56%) transplanted in relapse achieved CR after autotransplantation. Of these, 61 (37%) recurred. Twenty-four of 119 patients (20%) transplanted in CR recurred. The probability of disease-free survival at 3 years was 46 (40–52)% for transplants in first relapse and 64 (53–72)% for those in second remission (P < 0.001). Overall survival at 3 years was 58 (52–64)% after transplantation in first relapse and 75 (66–83)% after transplantation in second CR (P < 0.001). In multivariate analysis, Karnofsky performance score <90% at transplant, abnormal serum LDH at transplant, and chemotherapy resistance were adverse prognostic factors for outcome.... [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results